First‐Line Palliative HER2‐Targeted Therapy in HER2‐Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab‐Based Therapy

BACKGROUND. Survival of patients with human epidermal growth receptor 2 (HER2)‐positive metastatic breast cancer (MBC) has improved dramatically since trastuzumab has become available, although the disease eventually progresses in most patients. This study investigates the outcome (overall survival...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Rier, Hánah N., Levin, Mark‐David, van Rosmalen, Joost, Bos, Monique M. E. M., Drooger, Jan C., de Jong, Paul, Portielje, Johanneke E. A., Elsten, Elisabeth M. P., Ten Tije, Albert‐Jan, Sleijfer, Stefan, Jager, Agnes
Formato: Artigo
Idioma:Inglês
Publicado: AlphaMed Press 2017
Assuntos:
Breast Cancer
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5553959/
https://ncbi.nlm.nih.gov/pubmed/28533475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0448
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares